Travere Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on November 2, 2026, reporting its financial results for the quarter ended September 30, 2026, via a press release attached as Exhibit 99.1.

Key Highlights

  • Filing date: November 2, 2026, the same date as the earliest event reported.
  • Reporting period: Financial results cover the quarter ended September 30, 2026.
  • Disclosure vehicle: Results were announced via a press release attached as Exhibit 99.1 to the current report.
  • Furnished, not filed: The filing states the information in Item 2.02 and Exhibit 99.1 is "being furnished and shall not be deemed 'filed'" for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Signatory: The report was signed by Eric Dube, Chief Executive Officer, on November 2, 2026.

Travere Therapeutics Reports Third-Quarter 2026 Financial Results via 8-K

Travere Therapeutics, Inc. (NASDAQ:TVTX), a Delaware-incorporated company headquartered at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130, filed a current report on November 2, 2026, disclosing financial results for the quarter ended September 30, 2026, under Item 2.02 (Results of Operations and Financial Condition) of Form 8-K.

According to the filing, the company issued a press release on November 2, 2026, announcing, "among other things, its financial results for the quarter ended September 30, 2026." That press release, along with accompanying information, is attached to the current report as Exhibit 99.1. The filing also includes a Cover Page Interactive Data File, embedded within the Inline XBRL document, listed as Exhibit 104.

The filing notes that the information furnished under Item 2.02 and in Exhibit 99.1 "shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing," unless the registrant expressly designates such information as filed or incorporated by reference. The registrant confirmed it is not an emerging growth company as defined under the applicable Securities Act and Exchange Act rules.

What Was Disclosed

Travere Therapeutics filed an 8-K on November 2, 2026, furnishing a press release as Exhibit 99.1 containing financial results for the quarter ended September 30, 2026. The disclosure was furnished, not filed, under Section 18 of the Securities Exchange Act of 1934.